Clinical Trials Logo

Clinical Trial Summary

Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2.5 years is reached (whichever occurs first).


Clinical Trial Description

The study is a prospective, open-label, non-controlled, single-arm, multicentre phase III study. Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2.5 years is reached (whichever occurs first). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02627300
Study type Interventional
Source Octapharma
Contact
Status Completed
Phase Phase 3
Start date March 2016
Completion date September 5, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03677557 - Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment Phase 4
Completed NCT02810444 - Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID Phase 3
Enrolling by invitation NCT01150240 - Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland N/A
Recruiting NCT04944979 - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) Phase 3
Not yet recruiting NCT03252548 - Pediatric Primary Immunodeficiency Disease (PID) in China N/A
Completed NCT03961009 - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients Phase 3
Completed NCT04842643 - An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease Phase 3
Not yet recruiting NCT06089122 - Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG Phase 3
Not yet recruiting NCT06150833 - Efficacy and Safety and Pharmacokinetics of Boya IVIG Phase 3